NILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's disease.

7 The Baltimore Longitudinal Study of Ageing also found a strong trend towards reduced relative risk of AD in patients treated with DHP CCBs, with no lowered risk observed in the non-DHP CCB treatment group. 8 Furthermore, nilvadipine has been shown to have favourable effects on cognitive function with stabilisation of cognitive decline and reduced conversion to AD in patients with hypertension with mild cognitive impairment. 9 A study by Kennelly et al 10 provided preliminary evidence suggesting the potential efficacy in the treatment of AD.

also in 5,725 other papers